BioMedNewsBreaks

TuesdayDec 20, 2022 11:59 am

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Files Updated Life Sciences Presentation

India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation with the SEC on Form 8K. The presentation, available on the SEC website as well as published to IGC’s website, provides an overview of the company’s initiatives in life sciences. These include IGC’s focus on low-dose THC-based drug formulation and disease treatment and its various lines of cannabinoid-based consumer products. To view the full press release, visit https://ibn.fm/SmE91 About India Globalization Capital Inc. India Globalization Capital, through its subsidiary IGC Pharma LLC, develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s,…

Continue Reading

TuesdayDec 20, 2022 11:13 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady progress across our pipeline of differentiated psychedelic-based therapeutics and partnerships targeting mental health. Most notable were the advancements of our two lead programs, CYB003 and CYB004, into clinical stage – within less than 18 months since discovery – which is a remarkable accomplishment and a true testament to the strength of our team,” said Cybin’s Chief Executive Officer Doug Drysdale. “Along with our clinical programs,…

Continue Reading

FridayDec 16, 2022 3:42 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Game-Changing, Potentially Lifesaving GPS SmartSole in Canada

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, is a solution leader for consumers and patients with needs for remote monitoring. “MetAlert has announced that Canadian distributor Red Dot Alerts has launched the new award-winning 4G GPS SmartSole – a wearable medical monitoring device integrated into the orthotic insole allowing for discreet tracking and remote monitoring for those with Alzheimer’s, dementia and autism. The launch is supported by a marketing and advertising campaign, including radio and magazine ads and mailers to medical clinics, hospitals, pharmacies, and senior residence facilities across Canada. The advertising campaign…

Continue Reading

FridayDec 16, 2022 2:59 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Renowned Cardiologist to Help Define Best Paths to Advance Products

HeartBeam (NASDAQ: BEAT), a cardiac technology company, recently named a world-renowned interventional cardiologist with an impressive breadth of experience as its chief medical officer. “Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere… Dr. Fitzgerald joins HeartBeam after gaining invaluable experience in the clinical, research and industry sectors. An accomplished inventor, entrepreneur and investment-fund founder, Dr. Fitzgerald is serving as director of the Center for Cardiovascular Technology and director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School,” a recent article…

Continue Reading

FridayDec 16, 2022 12:12 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raise $8M

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit consists of one American Depositary Share (“ADS”) and two warrants; one warrant will expire three years from the date of issuance with the second warrant set to expire one year from the date of issuance.…

Continue Reading

FridayDec 16, 2022 10:22 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Shares Annual General Meeting Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2022 annual meeting. The meeting of shareholders was held Dec. 15, 2022. During the meeting, shareholders considered and voted on all matters outlined in InMed’s notice of meeting and management information circular. Specifically, the election of directors was held, and shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders. Those directors included Eric Adams, Andrew Hull, Janet Grove, Bryan Baldasare, and Nicole Lemerond. To view…

Continue Reading

WednesdayDec 14, 2022 3:55 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Approval to Dual List, to Commence Trading on Upstream

Nutriband (NASDAQ: NTRB, NTRBW) has announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. The company’s trading is expected to commence on Upstream under ticker symbol NTRB at 10:00am ET on Jan. 5, 2023. “Building shareholder value and increasing our liquidity is always a high priority for us,” said Gareth Sheridan, CEO of Nutriband. “We believe a dual listing on Upstream will act as an excellent vehicle to reach an untapped international market of potential new shareholders. As we continue to develop…

Continue Reading

WednesdayDec 14, 2022 2:14 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. “Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This study is an adaptive,…

Continue Reading

TuesdayDec 13, 2022 3:47 pm

BioMedNewsBreaks – IBN, BioMedWire to Deliver Increased Visibility, Reach for DGE’s 2023 Events

IBN (“InvestorBrandNetwork”), a multifaceted communications organization engaged in connecting companies to the investment community through 50+ brands, has announced that it will collaborate with Dynamic Global Events (“DGE”) as an official media partner for upcoming events in 2023. In addition, BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of IBN’s 50+ brands, will serve as an official media partner for DGE’s events throughout the coming year. A world leader in life sciences-related conference production, DGE has developed a portfolio of high-quality B2B events that facilitate partnership-building, education and networking throughout the pharmaceutical, health care and…

Continue Reading

TuesdayDec 13, 2022 3:41 pm

BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event

Keros (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders, announced that it presented clinical and preclinical data at the 64th American Society of Hematology (“ASH”) Annual Meeting and Exposition. The event was held in person and virtually from Dec. 10 -13, 2022. “We are pleased to present clinical and preclinical data from our lead hematological programs at ASH this year. In our ongoing phase 2 clinical trial in MDS, we observed a sustained response with longer-term treatment with KER-050 across all transfusion burdens.…

Continue Reading